RGLS4326 Granted Orphan Drug Designation for Treatment of ADPKD
In a recent press release, biopharmaceutical company Regulus Therapeutics, Inc. announced that their drug candidate, RGLS4326, received Orphan Drug Designation for the treatment of
The PKD Foundation is the only organization in the U.S. solely dedicated to finding treatments and a cure for polycystic kidney disease (PKD) and to improving the lives of those it affects. Since 1982, we have proudly funded more than $50 million in PKD research and leveraged $1.5 billion in government funding, while serving our local communities across the country. We are inspired by our mission. And driven by our vision.
Here is a list of conditions this partner raises awareness and advocacy for:
In a recent press release, biopharmaceutical company Regulus Therapeutics, Inc. announced that their drug candidate, RGLS4326, received Orphan Drug Designation for the treatment of
In 2015 families in Wales and England were given the good news that tolvaptan (JINARC®), which was developed for autosomal dominant polycystic kidney disease (ADPKD),
By Danielle Bradshaw from In The Cloud Copy Researchers in Germany have gone on record saying that there is a concern with how well patients
By Danielle Bradshaw from In The Cloud Copy Bill Bradford has made helping others a lifelong habit, but now this veteran and former paramedic needs
By Rachel Whetstone from In The Cloud Copy Peggy Nipper was struggling with polycystic kidney disease (PKD). Her kidneys were beginning to fail after developing
By Rachel Whetstone from In The Cloud Copy Shelly Wheaton began a car sign campaign in September to look for a live kidney donor.
© Copyright Patient Worthy
Join PW
We’ve heard your feedback. Now, by creating a login below, you can customize your homepage to the rare conditions that are most important to you. You can also share your rare story directly through the site, so being part of our community is easier than ever!